ImmunoGen Inc (IMGN)

NASDAQ
5.790
-0.110(-1.86%)
After Hours
5.970
+0.180(+3.109%)
- Real-time Data
  • Volume:
    1,353,849
  • Bid/Ask:
    5.790/5.980
  • Day's Range:
    5.760 - 6.000

IMGN Overview

Prev. Close
5.9
Day's Range
5.76-6
Revenue
136.65M
Open
6
52 wk Range
4.97-10.88
EPS
-0.29
Volume
1,353,849
Market Cap
1.17B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,314,508
P/E Ratio
-
Beta
1.22
1-Year Change
5.85%
Shares Outstanding
202,404,930
Next Earnings Date
Feb 11, 2022
What is your sentiment on ImmunoGen Inc?
or
Market is currently closed. Voting is open during market hours.

ImmunoGen Inc News

ImmunoGen Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

ImmunoGen Inc Company Profile

ImmunoGen Inc Company Profile

Employees
79

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

Read More
  • hi, anyone has any idea what is happening with this stock? ~30% down within 2 months?
    0
    • Correction
      0
  • whats happening? i mean why is the ~10% drop?
    1
    • because it increased around 2 dollars Last Thursday, I think this decrease is normal
      0
  • tell me the potencial of this company
    2
    • target price?
      0
    • lol what correction the earning is huge still crazy cheap 100 EOY
      1
      • Target and Correction till $9.60 is possible at first Eatery: 10.80 Tp: 9:60
        0
        • Correction till $9.60 is possible at first
          0
          • lets make this popular on reddit
            1
            • squeeze it;
              0
              • Seems it is a good beat.
                0
                • Is it a nice double beat?
                  0
                  • Is it a double super beat?
                    0
                    • Any chance to reach 9 dollars again?
                      1
                      • If the 4th quarter reportwill be fine, I think it could reach 8 or 8.2
                        0
                      • now 10 :)
                        0
                    • IMGN very interesting volume now. Watch seriously this stock
                      0
                      • any chance to reach 6 dollars again?
                        0
                        • Good price!
                          0
                          • target $5,50
                            0
                            • Too many sh... companies like this, $1,5 get in?
                              0
                              • time look at this closely
                                0
                                • will be back above 3.50 monday data being released AM
                                  2
                                  • I hadn't heard about a second offering.
                                    0
                                    • Tuesday
                                      0
                                      • When will the secondary offering take place
                                        0
                                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.